Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. probiotears

PROBIOTEARS SIGNED

Probiotic-based Ophtalmologic treatment for Bacterial and Allergic Conjunctivitis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 PROBIOTEARS project word cloud

Explore the words cloud of the PROBIOTEARS project. It provides you a very rough idea of what is the project "PROBIOTEARS" about.

broad    generate    solution    carry    dimension    formulation    micro    pharmaceutical    rising    14m    company    pathogenic    presented    toxicity    antibiotic    animal    million    organisms    worldwide    probiotics    resistances    faster    live    strains    tests    functional    infections    expertise    reestablishment    supportive    innovation    feasibility    industry    suitable    risks    issue    clinical    antagonism    inflammatory    covered    protection    conjunctivitis    bacterial    healthy    deeper    treatments    ready    ointments    ipr    trials    intraocular    stable    avoidance    antihistaminic    ophthalmologists    associations    ocular    scaling    resistance    galenic    safety    allergic    competitor    ophthalmic    1100    mainly    probiotic    eye    drugs    fast    people    market    solid    reinforce    drops    pressure    ingredients    models    validated    strain    formula    regulatory    microbiota    industrial    undesired    ab    global    strategy    ebitda    vivo    histaminic    pathogens    biotics    probiotears    aligned    health    perform    innovative    anti    recurrent    vitro   

Project "PROBIOTEARS" data sheet

The following table provides information about the project.

Coordinator		 AB BIOTICS SA 

Organization address
address: CALLE PARC DE RECERCA UAB CAMPUS AUB EDIFICIO DESPACHO P2M1 BELLATERRA
city: CERDANYOLA DEL VALLES
postcode: 8193
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Spain [ES]
 Project website http://www.ab-biotics.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.2.4. (Sustainable and competitive bio-based industries and supporting the development of a European bioeconomy)
2. H2020-EU.3.2.1. (Sustainable agriculture and forestry)
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.3.2.2. (Sustainable and competitive agri-food sector for a safe and healthy diet)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-10-01   to  2018-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AB BIOTICS SA ES (CERDANYOLA DEL VALLES) coordinator 50˙000.00

Map

 Project objective

Conjunctivitis is a major health issue affecting more than 1100 million people worldwide. Currently, the market for bacterial & allergic conjunctivitis is mainly covered by antibiotic eye drops and ointments, which have undesired effects in the eye microbiota and contribute to increase the resistances of pathogenic strains. Other treatments such as anti-inflammatory and antihistaminic drugs have also undesired side effects and are not useful as an immediate solution.

AB-BIOTICS, a company with a broad expertise in developing functional ingredients for the pharmaceutical industry, has developed an innovative solution based on the use of probiotics. Probiotics are live micro-organisms allowing a fast and stable reestablishment of a healthy eye microbiota by providing: (1) faster anti-inflammatory and anti-histaminic effects; (2) antagonism to pathogens with no resistance risks; (3) protection against future/recurrent infections; and (4) avoidance of common side effects such as intraocular pressure rising.

The effects of the selected probiotic strains have been validated through functional in vitro and in vivo tests and its safety for ocular application has also been assessed in toxicity trials in animal models. The industrial scaling up of the strain has already been achieved and is now ready for galenic formulation.

In order to determine the key steps to bring PROBIOTEARS to the market within the next 2 years, the objectives of the presented feasibility study are: • Assess clinical ophthalmologists & users associations interest • Determine the most suitable formula for ophthalmic use • Define IPR strategy • Perform a deeper market & competitor analysis • Find key partners to carry out Supportive Clinical Trials in phase 2 • Assess Regulatory Requirements

PROBIOTEARS is a solid high-potential innovation project aligned with AB-BIOTICS’ strategy which is expected to reinforce its European & global dimension, and generate an EBITDA of 2,14M€.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PROBIOTEARS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PROBIOTEARS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.2.4.;H2020-EU.3.2.1.;H2020-EU.2.3.1.;H2020-EU.3.2.2.)

KEEP-IT-UP (2018)

KEEP-IT-UP: Redefining shelf life monitoring in the global food industry with a new intelligent Time-Temperature Indicator for perishable products

Read More  

ARMeD_free (2017)

Antibiotic resistance-free meat and dairy products

Read More  

FucoPol (2017)

An innovative bio-based platform for the cost-competitive production of L-fucose, a building block for Human Milk Oligosaccharides (HMOs).

Read More